Autoimmunity and glomerulonephritis in mice with targeted deletion of the serum amyloid P component gene: SAP deficiency or strain combination?

Immunology

Volumn 112, Issue 2, 2004, Pages 255-264

  Gillmore, Julian D ^a   Hutchinson, Winston L ^a   Herbert, Jeff ^a   Bybee, Alison ^a   Mitchell, Daniel A ^b   Hasserjian, Robert P ^c   Yamamura, Ken Ichi ^d   Suzuki, Misao ^d   Sabin, Caroline A ^a   Pepys, Mark B ^a  

^a ROYAL FREE AND UNIVERSITY COLLEGE MEDICAL SCHOOL   (United Kingdom)

^b IMPERIAL COLLEGE LONDON   (United Kingdom)

^c MASSACHUSETTS GENERAL HOSPITAL   (United States)

^d KUMAMOTO UNIVERSITY   (Japan)

Author keywords

Autoimmunity; Glomerulonephritis; Knockouts; Transgenics

Indexed keywords

AMYLOID P COMPONENT;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIGEN ANTIBODY COMPLEX; ARTICLE; BINDING AFFINITY; CATABOLISM; CONTROLLED STUDY; FEMALE; GENE DELETION; GENE EXPRESSION; GENE TARGETING; GLOMERULONEPHRITIS; HEMIZYGOSITY; KIDNEY; KIDNEY FAILURE; LIVER; MORBIDITY; MORTALITY; MOUSE; NONHUMAN; PHENOTYPE; PRIORITY JOURNAL; PROTEINURIA; TRANSGENIC MOUSE;

ANIMALS; ANTIBODIES, ANTINUCLEAR; APOPTOSIS; AUTOIMMUNITY; CHROMATIN; DNA-BINDING PROTEINS; FEMALE; GLOMERULONEPHRITIS; HUMANS; IMMUNE COMPLEX DISEASES; IMMUNIZATION; KIDNEY; MALE; MICE; MICE, INBRED C57BL; MICE, KNOCKOUT; MICE, TRANSGENIC; NUCLEOSOMES; RHEUMATOID FACTOR; SERUM AMYLOID P-COMPONENT;

EID: 2542580839     PISSN: 00192805     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1365-2567.2004.01860.x     Document Type: Article

References (31)

1. Pepys MB, Booth DR, Hutchinson WL, Gallimore JR, Collins PM, Hohenester E. Amyloid P component. A critical review. Amyloid: Int J Exp Clin Invest 1997; 4:274-95.
2. Pepys MB, Butler PJG. Serum amyloid P component is the major calcium-dependent specific DNA binding protein of the serum. Biochem Biophys Res Commun 1987; 148:308-13.
3. Butler PJG, Tennent GA, Pepys MB. Pentraxin-chromatin interactions: serum amyloid P component specifically displaces H1-type histones and solubilizes native long chromatin. J Exp Med 1990; 172:13-18.
4. Pepys MB, Booth SE, Tennent GA, Butler PJG, Williams DG. Binding of pentraxins to different nuclear structures. C-reactive protein binds to small nuclear ribonucleoprotein particles, serum amyloid P component binds to chromatin and nucleoli. Clin Exp Immunol 1994; 97:152-7.
5. Breathnach SM, Kofler H, Sepp N, Ashworth J, Woodrow D, Pepys MB, Hintner H. Serum amyloid P component binds to cell nuclei in vitro and to in vivo deposits of extracellular chromatin in systemic lupus erythematosus. J Exp Med 1989; 170:1433-8.
6. Hintner H, Booker J, Ashworth J, Auböck J, Pepys MB, Breathnach SM. Amyloid P component binds to keratin bodies in human skin and to isolated keratin filament aggregates in vitro. J Invest Dermatol 1988; 91:22-8.
7. Familian A, Zwart B, Huisman HG, Rensink I, Roem D, Hordijk PL, Aarden LA, Hack CE. Chromatin-independent binding of serum amyloid P component to apoptotic cells. J Immunol 2001; 167:647-54.
8. Bickerstaff MCM, Botto M, Hutchinson WL et al. Serum amyloid P component controls chromatin degradation and prevents antinuclear autoimmunity. Nature Med 1999; 5:694-7.
9. Botto M, Hawkins PN, Bickerstaff MCM et al. Amyloid deposition is delayed in mice with targeted deletion of the serum amyloid P component gene. Nature Med 1997; 3:855-9.
10. Mitchell DA, Pickering MC, Warren J, Fossati-Jimack L, Cortes-Hernandez J, Cook HT, Botto M, Walport MJ. C1q deficiency and autoimmunity: the effects of genetic background on disease expression. J Immunol 2002; 168:2538-43.
11. Iwanaga T, Wakasugi S, Inomoto T et al. Liver-specific and high-level expression of human serum amyloid P component gene in transgenic mice. Dev Genet 1989; 10:365-71.
12. Yamamura K-I, Tashiro F, Yi S, Wakasugi S, Araki S, Maeda S, Shimada K. Transgenic mouse model for human genetic diseases. Mol Reprod Dev 1993; 36:248-50.
13. Pepys MB, Dash AC, Markham RE, Thomas HC, Williams BD, Petrie A. Comparative clinical study of protein SAP (amyloid P component) and C-reactive protein in serum. Clin Exp Immunol 1978; 32:119-24.
14. Mackay F, Woodcock SA, Lawton P, Ambrose C, Baetscher M, Schneider P, Tschopp J, Browning JL. Mice transgenic for BAFF develop lymphocytic disorders along with autoimmune manifestations. J Exp Med 1999; 190:1697-710.
15. Mather SJ, Ward BG. High efficiency iodination of monoclonal antibodies for radiotherapy. J Nucl Med 1987; 28:1034-6.
16. Pittman RC, Carew TE, Glass CK, Green SR, Taylor CRJ, Attie AD. A radioiodinated, intracellularly trapped ligand for determining the sites of plasma protein degradation. Biochem J 1983; 212:791-800.
17. Hutchinson WL, Noble GE, Hawkins PN, Pepys MB. The pentraxins, C-reactive protein and serum amyloid P component, are cleared and catabolized by hepatocytes in vivo. J Clin Invest 1994; 94:1390-6.
18. Herbert J, Hutchinson WL, Carr J, Ives J, Jakob-Roetne R, Yamamura K, Suzuki M, Pepys MB. Influenza virus infection is not affected by serum amyloid P component. Mol Med 2002; 8:9-15.
19. Hayashi Y, Utsuyama M, Kurashima C, Hirokawa K. Spontaneous development of organ-specific autoimmune lesions in aged C57BL/6 mice. Clin Exp Immunol 1989; 78:120-6.
20. Leadbetter EA, Rifkin IR, Hohlbaum AM, Beaudette BC, Shlomchik MJ, Marshak-Rothstein A. Chromatin-IgG complexes activate B cells by dual engagement of IgM and Toll-like receptors. Nature 2002; 416:603-7.
21. Robson MG, Cook HT, Botto M et al. Accelerated nephrotoxic nephritis is exacerbated in C1q-deficient mice. J Immunol 2001; 166:6820-8.
22. Mevorach D, Zhou JL, Song X, Elkon KB. Systemic exposure to irradiated apoptotic cells induces autoantibody production. J Exp Med 1998; 188:387-92.
23. Mohan C, Morel L, Yang P, Wakeland EK. Genetic dissection of systemic lupus erythematosus pathogenesis. Sle2 on murine chromosome 4 leads to B cell hyperactivity. J Immunol 1997; 159:454-65.
24. Mohan C, Alas E, Morel L, Yang P, Wakeland EK. Genetic dissection of SLE pathogenesis. Sle1 on murine chromosome 1 leads to a selective loss of tolerance to H2A/H2B/DNA subnucleosomes. J Clin Invest 1998; 101:1362-72.
25. Mohan C, Morel L, Yang P, Watanabe H, Croker B, Gilkeson G, Wakeland EK. Genetic dissection of lupus pathogenesis: a recipe for nephrophilic autoantibodies. J Clin Invest 1999; 103:1685-95.
26. Botto M, Dell'Agnola C, Bygrave AE et al. Homozygous C1q deficiency causes glomerulonephritis associated with multiple apoptotic bodies. Nature Genet 1998; 19:56-9.
27. 123I- labeled serum amyloid P component. J Exp Med 1988; 167:903-13.
28. Pepys MB, Herbert J, Hutchinson WL et al. Targeted pharmacological depletion of serum amyloid P component for treatment of human amyloidosis. Nature 2002; 417:254-9.
29. Morel L, Mohan CYuY, Croker BP, Tian N, Deng A, Wakeland EK. Functional dissection of systemic lupus erythematosus using congenic mouse strains. J Immunol 1997; 158:6019-28.
30. Morel L, Blenman KR, Croker BP, Wakeland EK. The major murine systemic lupus erythematosus susceptibility locus, Sle1, is a cluster of functionally related genes. Proc Natl Acad Sci USA 2001; 98:1787-92.
31. Noursadeghi M, Bickerstaff MCM, Gallimore JR, Herbert J, Cohen J, Pepys MB. Role of serum amyloid P component in bacterial infection: protection of the host or protection of the pathogen. Proc Natl Acad Sci USA 2000; 97:14584-9.